UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Therapeutic approaches in Parkinson's disease and related disorders

Journal of neurochemistry, 2016-10, Vol.139 (S1), p.346-352

2016

Volltextzugriff (PDF)

The neuropathology of multiple system atrophy and its therapeutic implications

Autonomic neuroscience, 2018-05, Vol.211, p.1-6

2018

Volltextzugriff (PDF)

Combination therapies: The next logical Step for the treatment of synucleinopathies?

Movement disorders, 2016-02, Vol.31 (2), p.225-234

2016

Volltextzugriff (PDF)

Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials

Acta neuropathologica, 2014-06, Vol.127 (6), p.861-879

2014

Volltextzugriff (PDF)

Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease

Journal of neuroinflammation, 2015-05, Vol.12 (1), p.93, Article 93

2015

Volltextzugriff (PDF)

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy

Molecular neurodegeneration, 2015-03, Vol.10 (1), p.10-10, Article 10

2015

Volltextzugriff (PDF)

Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies

Pharmacology & therapeutics (Oxford), 2013-06, Vol.138 (3), p.311-322

2013

Volltextzugriff (PDF)

Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease

PloS one, 2017-04, Vol.12 (4), p.e0174630-e0174630

2017

Volltextzugriff (PDF)

MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy

Frontiers in molecular neuroscience, 2017-10, Vol.10, p.329-329

2017

Volltextzugriff (PDF)

BMP-2/6 heterodimer is more effective than BMP-2 or BMP-6 homodimers as inductor of differentiation of human embryonic stem cells

PloS one, 2010-06, Vol.5 (6), p.e11167-e11167

2010

Volltextzugriff (PDF)

Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders

Neurotherapeutics, 2016-01, Vol.13 (1), p.179-189

2016

Volltextzugriff (PDF)

Alterations in Striatal microRNA-mRNA Networks Contribute to Neuroinflammation in Multiple System Atrophy

Molecular neurobiology, 2019-10, Vol.56 (10), p.7003-7021

2019

Volltextzugriff (PDF)

Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy

Glia, 2014-02, Vol.62 (2), p.317-337

2014

Volltextzugriff (PDF)

Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models

The Journal of neuroscience, 2014-07, Vol.34 (28), p.9441-9454

2014

Volltextzugriff (PDF)

Immunotherapy for neurodegenerative diseases: Focus on I--synucleinopathies

Pharmacology & therapeutics (Oxford), 2013-06, Vol.138 (3), p.311-322

2013

Volltextzugriff (PDF)

Multiple system atrophy: experimental models and reality

Acta neuropathologica, 2018-01, Vol.135 (1), p.33-47

2018

Volltextzugriff (PDF)

Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril

Scientific reports, 2016-08, Vol.6 (1), p.30891-30891, Article 30891

2016

Volltextzugriff (PDF)

Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy

Neuropathology and applied neurobiology, 2016-02, Vol.42 (1), p.95-106

2016

Volltextzugriff (PDF)

Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease

The Journal of neuroscience, 2013-06, Vol.33 (25), p.10512-10525

2013

Volltextzugriff (PDF)

Alterations in brain TREM2 and Amyloid‐β levels are associated with neurocognitive impairment in HIV‐infected persons on antiretroviral therapy

Journal of neurochemistry, 2018-12, Vol.147 (6), p.784-802

2018

Volltextzugriff (PDF)

A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy

Molecular neurodegeneration, 2015-09, Vol.10 (1), p.48-48, Article 48

2015

Volltextzugriff (PDF)

A novel N-methyl-D-aspartate receptor open channel blocker with in vivo neuroprotectant activity

The Journal of pharmacology and experimental therapeutics, 2002-07, Vol.302 (1), p.163

2002

Volltextzugriff (PDF)

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy

Acta neuropathologica communications, 2017-01, Vol.5 (1), p.7-7, Article 7

2017

Volltextzugriff (PDF)

α-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy

Acta neuropathologica, 2016-07, Vol.132 (1), p.59-75

2016

Volltextzugriff (PDF)

Alterations in brain TREM 2 and Amyloid‐β levels are associated with neurocognitive impairment in HIV ‐infected persons on antiretroviral therapy

Journal of neurochemistry, 2018-12, Vol.147 (6), p.784-802

2018

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(48)
Reviews
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Therapeutic approaches in Parkinson's disease and related disorders

The neuropathology of multiple system atrophy and its therapeutic implications

Combination therapies: The next logical Step for the treatment of synucleinopathies?

Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials

Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy

Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies

Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease

MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy

BMP-2/6 heterodimer is more effective than BMP-2 or BMP-6 homodimers as inductor of differentiation of human embryonic stem cells

Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders

Alterations in Striatal microRNA-mRNA Networks Contribute to Neuroinflammation in Multiple System Atrophy

Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy

Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models

Immunotherapy for neurodegenerative diseases: Focus on I--synucleinopathies

Multiple system atrophy: experimental models and reality

Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril

Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy

Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease

Alterations in brain TREM2 and Amyloid‐β levels are associated with neurocognitive impairment in HIV‐infected persons on antiretroviral therapy

A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy

A novel N-methyl-D-aspartate receptor open channel blocker with in vivo neuroprotectant activity

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy

α-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy

Alterations in brain TREM 2 and Amyloid‐β levels are associated with neurocognitive impairment in HIV ‐infected persons on antiretroviral therapy

Suchergebnisse filtern